お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
923888

ワクチンの世界市場:技術、疾患(肺炎球菌、インフルエンザ、DTP、ロタウイルス、TT、ポリオ、MMR、水痘、デング、結核、帯状疱疹、狂犬病)、投与経路別、患者、タイプ別 - 2024年までの予測

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 189 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
ワクチンの世界市場:技術、疾患(肺炎球菌、インフルエンザ、DTP、ロタウイルス、TT、ポリオ、MMR、水痘、デング、結核、帯状疱疹、狂犬病)、投与経路別、患者、タイプ別 - 2024年までの予測
出版日: 2020年01月29日
発行: MarketsandMarkets
ページ情報: 英文 189 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチンの世界市場は2019年の417億米ドルからCAGR7.0%で拡大し、2024年までに584億米ドルに達すると予測されています。同市場の成長を促進しているのは、感染症の高い罹患率、ワクチンの研究開発に対する支援の増強、ワクチン開発への投資、予防接種に対する注目度の高まりなどです。一方で、ワクチン開発に要する巨額の資本投資が市場の成長を抑制する可能性もあります。

当レポートでは、ワクチンの世界市場について調査し、セグメント別動向、2024年までの成長予測、地域別動向、および市場に参入する企業のプロファイルなどについてまとめています。

923888_4.1 VACCINES MARKET OVERVIEW_FIGURE 13

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 プレミアムインサイト

第5章 市場概要

  • イントロダクション
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 課題
    • 火急の問題

第6章 業界動向

  • 法規制環境
  • 主なパイプライン製品
  • 新たなワクチンの機会
    • HIV
    • マラリア
    • ジカ
    • エボラ

第7章 ワクチン市場:技術別

  • イントロダクション
  • 結合ワクチン
  • 不活化、サブユニットワクチン
  • 生ワクチン
  • 組み換えワクチン
  • トキソイドワクチン

第8章 ワクチン市場:タイプ別

  • イントロダクション
  • 単価ワクチン
  • 多価ワクチン

第9章 ワクチン市場:疾患適応別

  • イントロダクション
  • 肺炎球菌
  • インフルエンザ
  • DTP
  • HPV
  • 髄膜炎菌性疾患
  • 肝炎
  • ポリオ
  • ロタウイルス
  • MMR
  • 帯状疱疹
  • 水痘
  • その他

第10章 ワクチン市場:投与経路別

  • イントロダクション
  • 筋肉内、皮下投与
  • 経口投与
  • その他

第11章 ワクチン市場:患者タイプ別

  • イントロダクション
  • 小児患者
  • 成人患者

第12章 ワクチン市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他の諸国

第13章 競合環境

  • 概要
  • 市場シェア分析
  • 競合リーダーシップマッピング
  • 競合動向

第14章 企業プロファイル

第15章 付録

図表

LIST OF TABLES

  • TABLE 1 INCIDENCE OF INFECTIOUS DISEASES
  • TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2014-2020 (USD MILLION)
  • TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2016 VS. 2018
  • TABLE 4 REGULATORY AUTHORITIES IN EUROPE
  • TABLE 5 REGULATORY AUTHORITIES IN ASIA
  • TABLE 6 KEY PIPELINE VACCINES
  • TABLE 7 VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 8 COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR PEDIATRIC PATIENTS
  • TABLE 9 COST OF MENINGOCOCCAL CONJUGATE VACCINES FOR ADULT PATIENTS
  • TABLE 10 CONJUGATE VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 11 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
  • TABLE 12 INACTIVATED & SUBUNIT VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 13 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 14 EXAMPLES OF RECOMBINANT VACCINES
  • TABLE 15 RECOMBINANT VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16 TOXOID VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 17 VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 18 MONOVALENT VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 19 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET
  • TABLE 20 MULTIVALENT VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 21 VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 22 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
  • TABLE 23 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 24 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
  • TABLE 25 INFLUENZA VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 26 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
  • TABLE 27 DTP VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 28 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
  • TABLE 29 HPV VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 30 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET
  • TABLE 31 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 32 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
  • TABLE 33 HEPATITIS VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 34 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET
  • TABLE 35 POLIO VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 36 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
  • TABLE 37 ROTAVIRUS VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 38 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
  • TABLE 39 MMR VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 40 HERPES ZOSTER VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
  • TABLE 42 VARICELLA VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 43 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
  • TABLE 44 OTHER DISEASE INDICATION VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 46 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
  • TABLE 47 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 48 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 49 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 50 VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 51 VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 52 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 53 VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 54 NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 55 VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 56 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 58 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 59 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 60 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 61 NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 62 NUMBER OF NEW INFECTIOUS DISEASE CASES IN THE US, 2017
  • TABLE 63 US: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 64 US: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 65 NUMBER OF NEW INFECTIOUS DISEASE CASES IN CANADA, 2015-2017
  • TABLE 66 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 67 CANADA: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 68 EUROPE: VACCINES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 69 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 70 EUROPE: VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 71 EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 72 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 73 EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 74 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 75 UK: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 76 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 77 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 78 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 79 ROE: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 80 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 VS. 2014 VS. 2016 (USD)
  • TABLE 81 ASIA: VACCINES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 82 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 83 ASIA: VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 84 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 85 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 86 ASIA: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 87 DISEASE INCIDENCE IN JAPAN, 2016-2018
  • TABLE 88 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 89 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 90 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 91 ROA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 92 ROW: VACCINES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 93 ROW: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 94 ROW: VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 95 ROW: VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 96 ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 97 ROW: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 98 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 99 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 100 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 101 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 102 LATIN AMERICA: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)
  • TABLE 103 OTHER ROW COUNTRIES: VACCINES MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 104 OTHER ROW COUNTRIES: VACCINES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 105 OTHER ROW COUNTRIES: VACCINES MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION)
  • TABLE 106 OTHER ROW COUNTRIES: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION)
  • TABLE 107 OTHER ROW COUNTRIES: VACCINES MARKET, BY PATIENT TYPE, 2017-2024 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 VACCINES MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH
  • FIGURE 5 TOP-DOWN APPROACH
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • FIGURE 7 VACCINES MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8 VACCINES MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 9 VACCINES MARKET, BY DISEASE INDICATION, 2019 VS. 2024 (USD MILLION)
  • FIGURE 10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019 VS. 2024 (USD MILLION)
  • FIGURE 11 VACCINES MARKET, BY PATIENT TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 12 VACCINES MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 13 HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH
  • FIGURE 14 CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VACCINES MARKET IN 2018
  • FIGURE 15 ASIA TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET FROM 2019 TO 2024
  • FIGURE 16 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17 REGULATORY APPROVAL PROCESS FOR VACCINES
  • FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2024
  • FIGURE 19 NORTH AMERICA: VACCINES MARKET SNAPSHOT
  • FIGURE 20 EUROPE: VACCINES MARKET SNAPSHOT
  • FIGURE 21 ASIA: VACCINES MARKET SNAPSHOT
  • FIGURE 22 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
  • FIGURE 23 COMPETITIVE LEADERSHIP MAPPING: VACCINES MARKET (2018)
  • FIGURE 24 GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT (2018)
  • FIGURE 25 MERCK & CO., INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 26 PFIZER, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 27 SANOFI PASTEUR SA: COMPANY SNAPSHOT (2018)
  • FIGURE 28 CSL LIMITED: COMPANY SNAPSHOT (2018)
  • FIGURE 29 EMERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2018)
  • FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2018)
  • FIGURE 32 BAVARIAN NORDIC: COMPANY SNAPSHOT (2018)
  • FIGURE 33 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2018)
  • FIGURE 34 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2018)
  • FIGURE 35 PANACEA BIOTEC: COMPANY SNAPSHOT (2018)
目次
Product Code: PH 6528

"The vaccines market is projected to grow at a CAGR of 7.0% during the forecast period (2019-2024)."

The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The key factors driving the growth of this market include the high prevalence of infectious diseases, growing support for vaccine R&D, investments in vaccine development, and rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

"The pneumococcal disease segment will continue to dominate the vaccines market during the forecast period."

On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.

"By type, the monovalent vaccines segment accounted for the larger share of the vaccines market in 2019."

On the basis of type, the vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government & non-government initiatives to promote immunization.

"The market in Asia is projected to witness the highest growth rate during the forecast period (2019-2024)."

Asia is projected to register the highest growth during the forecast period. Growing company investments in Asian countries and rising government support for vaccine development are some of the key factors supporting the growth of the vaccines market in Asia.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1: 47%, Tier 2: 26%, and Tier 3: 27%
  • By Designation: C-level: 33%, Director-level: 21%, and Others: 46%
  • By Region: North America: 36%, Europe: 31%, Asia: 16%, and the RoW: 17%

GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), and Merck & Co., Inc. (US) are the leading players in the global vaccines market. Other notable players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd (China), Incepta Vaccine LTD. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and Bio Farma (Brazil).

Research Coverage:

The report analyzes the vaccines market and aims at estimating the market size and future growth potential of this market based on various segments such as technology, type, disease indication, route of administration, patient type, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyzes the market based on technology, type, disease indication, route of administration, patient type, and region.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the vaccines market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of vaccines across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the vaccines market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the vaccines market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primaries
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 DATA TRIANGULATION APPROACH
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 VACCINES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY (2018)
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 High prevalence of infectious diseases
      • 5.2.1.2 Rising focus on immunization programs
      • 5.2.1.3 Growing government support for vaccine development
      • 5.2.1.4 Increasing company initiatives to enhance vaccine R&D
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of vaccine development
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth prospects in emerging markets
      • 5.2.3.2 Focus on therapeutic vaccines
      • 5.2.3.3 Use of adjuvants in vaccines
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Inadequate access to vaccines
    • 5.2.5 BURNING ISSUES
      • 5.2.5.1 Product recalls

6 INDUSTRY INSIGHTS

  • 6.1 REGULATORY LANDSCAPE
    • 6.1.1 NORTH AMERICA
    • 6.1.2 EUROPE
    • 6.1.3 ASIA
    • 6.1.4 ROW
  • 6.2 KEY PIPELINE PRODUCTS
  • 6.3 NEW VACCINE OPPORTUNITIES
    • 6.3.1 HIV
      • 6.3.1.1 HIV vaccine: product pipeline
      • 6.3.1.2 HIV vaccine: public-private initiatives
      • 6.3.1.3 HIV vaccine: funding
    • 6.3.2 MALARIA
      • 6.3.2.1 Malaria vaccine: product pipeline
      • 6.3.2.2 Malaria vaccine: public-private initiatives
    • 6.3.3 ZIKA
      • 6.3.3.1 Zika vaccine: product pipeline
      • 6.3.3.2 Zika vaccine: public-private initiatives
      • 6.3.3.3 Zika vaccine: funding
    • 6.3.4 EBOLA
      • 6.3.4.1 Ebola vaccine: product pipeline
      • 6.3.4.2 Ebola vaccine: public-private initiatives
      • 6.3.4.3 Ebola vaccine: funding
      • 6.3.4.4 Ebola projects funded by EC (2014-2020)

7 VACCINES MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 CONJUGATE VACCINES
    • 7.2.1 CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET
  • 7.3 INACTIVATED & SUBUNIT VACCINES
    • 7.3.1 EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR
  • 7.4 LIVE ATTENUATED VACCINES
    • 7.4.1 ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH
  • 7.5 RECOMBINANT VACCINES
    • 7.5.1 LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES
  • 7.6 TOXOID VACCINES
    • 7.6.1 COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH

8 VACCINES MARKET, BY TYPE

  • 8.1 INTRODUCTION
  • 8.2 MONOVALENT VACCINES
    • 8.2.1 IN 2018, THE MONOVALENT VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
  • 8.3 MULTIVALENT VACCINES
    • 8.3.1 INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES ARE DRIVING THE GROWTH OF THIS SEGMENT

9 VACCINES MARKET, BY DISEASE INDICATION

  • 9.1 INTRODUCTION
  • 9.2 PNEUMOCOCCAL DISEASE
    • 9.2.1 PNEUMOCOCCAL DISEASE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
  • 9.3 INFLUENZA
    • 9.3.1 INFLUENZA VACCINES SEGMENT TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • 9.4 DTP
    • 9.4.1 INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH
  • 9.5 HPV
    • 9.5.1 GROWING PREVALENCE OF HPV INFECTIONS TO SUPPORT MARKET GROWTH
  • 9.6 MENINGOCOCCAL DISEASE
    • 9.6.1 RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
  • 9.7 HEPATITIS
    • 9.7.1 HIGH PREVALENCE OF HEPATITIS INFECTIONS IS DRIVING THE DEMAND FOR IMMUNIZATION
  • 9.8 POLIO
    • 9.8.1 GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS MARKET SEGMENT
  • 9.9 ROTAVIRUS
    • 9.9.1 RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH
  • 9.10 MMR
    • 9.10.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA WILL SUPPORT THE GROWTH OF THIS MARKET SEGMENT
  • 9.11 HERPES ZOSTER
    • 9.11.1 HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING THE FORECAST PERIOD
  • 9.12 VARICELLA
    • 9.12.1 PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES
  • 9.13 OTHER DISEASE INDICATIONS

10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1 INTRODUCTION
  • 10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
    • 10.2.1 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
  • 10.3 ORAL ADMINISTRATION
    • 10.3.1 POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA MAY LIMIT THE GROWTH OF THIS SEGMENT
  • 10.4 OTHER ROUTES OF ADMINISTRATION

11 VACCINES MARKET, BY PATIENT TYPE

  • 11.1 INTRODUCTION
  • 11.2 PEDIATRIC PATIENTS
    • 11.2.1 IN 2018, THE PEDIATRIC PATIENTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
  • 11.3 ADULT PATIENTS
    • 11.3.1 THE ADULT PATIENTS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

12 VACCINES MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 US
      • 12.2.1.1 The US is the largest market for vaccines
    • 12.2.2 CANADA
      • 12.2.2.1 High incidence of infectious diseases is driving the demand for vaccines in the country
  • 12.3 EUROPE
    • 12.3.1 GERMANY
      • 12.3.1.1 Significant investments in R&D to support market growth
    • 12.3.2 UK
      • 12.3.2.1 Launch of new products to support market growth in the UK in the coming years
    • 12.3.3 FRANCE
      • 12.3.3.1 Favorable government initiatives for immunization to support market growth in France
    • 12.3.4 ITALY
      • 12.3.4.1 Conjugate vaccines to account for the largest share of the Italian market
    • 12.3.5 SPAIN
      • 12.3.5.1 Rising investments in vaccine development by private organizations to support market growth in Spain
    • 12.3.6 REST OF EUROPE
  • 12.4 ASIA
    • 12.4.1 JAPAN
      • 12.4.1.1 Government initiatives for increasing the accessibility of vaccines to drive market growth in Japan
    • 12.4.2 CHINA
      • 12.4.2.1 Growing investments in the biotechnology sector to drive market growth in China
    • 12.4.3 INDIA
      • 12.4.3.1 Growth of the biotechnology sector and development of new vaccines to support market growth in India
    • 12.4.4 REST OF ASIA
  • 12.5 REST OF THE WORLD
    • 12.5.1 LATIN AMERICA
    • 12.5.2 OTHER ROW COUNTRIES

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 MARKET SHARE ANALYSIS
  • 13.3 COMPETITIVE LEADERSHIP MAPPING (2018)
    • 13.3.1 VISIONARY LEADERS
    • 13.3.2 INNOVATORS
    • 13.3.3 DYNAMIC DIFFERENTIATORS
    • 13.3.4 EMERGING COMPANIES
  • 13.4 COMPETITIVE SITUATION AND TRENDS
    • 13.4.1 AGREEMENTS, CONTRACTS, AND COLLABORATIONS
    • 13.4.2 PRODUCT LAUNCHES & APPROVALS
    • 13.4.3 ACQUISITIONS
    • 13.4.4 EXPANSIONS

14 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 14.1 GLAXOSMITHKLINE PLC.
  • 14.2 MERCK & CO., INC.
  • 14.3 PFIZER, INC.
  • 14.4 SANOFI PASTEUR SA
  • 14.5 CSL LIMITED
  • 14.6 EMERGENT BIOSOLUTIONS, INC.
  • 14.7 JOHNSON & JOHNSON
  • 14.8 ASTRAZENECA
  • 14.9 SERUM INSTITUTE OF INDIA PVT., LTD.
  • 14.10 BAVARIAN NORDIC
  • 14.11 MITSUBISHI TANABE PHARMA CORPORATION
  • 14.12 DAIICHI SANKYO COMPANY, LIMITED
  • 14.13 PANACEA BIOTEC, LTD.
  • 14.14 BIOLOGICAL E
  • 14.15 BHARAT BIOTECH
  • 14.16 OTHER COMPANIES
    • 14.16.1 SINOVAC BIOTECH, LTD.
    • 14.16.2 INCEPTA VACCINE, LTD.
    • 14.16.3 VALNEVA SE
    • 14.16.4 VBI VACCINES INC.
    • 14.16.5 PT BIO FARMA (PERSERO)

Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 AVAILABLE CUSTOMIZATIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.